MIA researchers feature on prestigious Highly Cited Researchers 2020 List
18 November 2020
Melanoma Institute Australia is proud to announce that MIA’s Co-Medical Directors, Professor Georgina Long AO and Professor Richard Scolyer, as well as MIA Faculty member Associate Professor Alex Menzies and former Faculty member Professor Rick Kefford AM, have been named on the annual Highly Cited Researchers™ 2020 list from Clarivate.
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe. It identifies researchers who demonstrated significant influence in their chosen field or fields through the publication of multiple highly cited papers during the last decade.
Their names are drawn from the publications that rank in the top 1% by citations for field and publication year in the Web of Science™ citation index.
According to Clarivate, 6,167 researchers from more than 60 countries and regions have been recognized this year, with Australian research institutes continuing to punch above their weight. In a country of just 25 million, the number of Australian researchers recognized in 2020 is 305.
MIA Co-Medical Director Professor Georgina Long AO, whose video interview with Clarivate is featured online, said:
“This accolade is recognition of the ground-breaking work being carried out by the entire team at Melanoma Institute Australia as we continue our quest to develop treatments that will ultimately save the lives of all melanoma patients.”
Fellow Co-Medical Director of MIA Professor Richard Scolyer said:
“It is an honour to again be included on this list alongside several other MIA researchers and clinicians. It shows the phenomenal and ongoing impact that MIA’s work and research is having around the world.”
David Pendlebury, Senior Citation Analyst at the Institute for Scientific Information at Clarivate said:
“In the race for knowledge, it is human capital that is fundamental and this list identifies and celebrates exceptional individual researchers from Melanoma Institute Australia who are having a great impact on the research community as measured by the rate at which their work is being cited by others.”
Melanoma Institute Australia is affiliated with The University of Sydney
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.